Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Re: Medical Students Can Help Counter Misleading Media and Political Narratives About Strikes
In a rapid response published on April 30, 2026, medical ethicist and barrister Daniel Sokol argues that medical students should refrain from discussing resident doctor strikes with patients. He warns that even brief explanations about workload pressures and patient‑safety motives can appear insensitive or patronising, especially when patients are already anxious about delayed care. The potential loss of trust, complaints, or disciplinary action, he contends, outweighs any benefit of countering misleading media narratives. Sokol’s stance underscores the need for clear boundaries in student‑patient interactions during labor disputes.
EnVVeno Medical Secures FDA IDE Approval for Venous Valve Study
enVVeno Medical has secured FDA investigational device exemption (IDE) approval to launch its pivotal Transcatheter Venous Valve Endoprosthesis (TAVVE) study, targeting severe chronic venous insufficiency (CVI). The trial will begin later this year with a ten‑patient safety cohort, followed by...
5 Ways Chromatography Advances Digital Diagnostics
Chromatography innovations—high‑resolution columns, automated sample‑prep kits, advanced filtration, native software interfaces, and scalable setups—are strengthening the data foundation of digital diagnostics. By delivering cleaner, reproducible chemical data, these technologies enable AI models and electronic health record systems to generate reliable,...
Precision Begins Patient Enrolment for FUNCTION-DMD Trial
Precision BioSciences has activated Arkansas Children’s Hospital as the inaugural site for its Phase I/II FUNCTION‑DMD trial, enrolling boys aged two to seven with Duchenne muscular dystrophy. The study tests PBGENE‑DMD, a first‑in‑class in‑vivo gene‑editing therapy that removes exons 45‑55 to restore...
How Epic Bio Is Leveraging CRISPR without Cutting DNA
Epic Bio, founded by Stanford professor Stanley Qi, is developing an epigenetic editing platform called GEMS that uses the smallest known Cas protein to modulate gene expression without cutting DNA. The system can be delivered in a single viral vector...
3D Systems Clears the EU Bar and Enters Europe’s Denture Market
U.S. printer maker 3D Systems has secured Class IIa MDR certification for its NextDent Jet Base, Jet Teeth materials and NextDent 300 MultiJet printer, unlocking commercial sales of a full‑denture printing system across the European Union starting May 4. The clearance lets dental...
Re: Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)
The phase‑3 PreVenTB trial found that neither VPM1002 nor Immuvac reduced microbiologically confirmed tuberculosis, missing its primary efficacy endpoint. The authors of a BMJ rapid response highlight that the headline claim of 50% efficacy against extrapulmonary TB rests on only...
Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
The European Commission has granted approval for Poherdy, a 420 mg/14 mL interchangeable biosimilar of pertuzumab (Perjeta), covering all approved indications. The decision rests on extensive analytical, pharmacokinetic, efficacy, safety and immunogenicity data that demonstrate equivalence to the reference product. Henlius has...
A Tale of Two Books: We Want Them Infected & In COVID’s Wake
The author contrasts his self‑published book *We Want Them Infected* with the Princeton‑authored *In COVID’s Wake*, noting that both address the U.S. pandemic response but diverge sharply in tone, reception, and political intent. *We Want Them Infected* compiles frontline accounts...
AI Moves From Proof-of-Concept to Proof-of-Return
McKinsey’s latest survey shows U.S. healthcare executives moving from experimenting with generative AI to demanding measurable returns. Half of the respondents have already deployed at least one GenAI use case, up from 25% two years ago, and 19% have adopted...
XPRIZE Healthspan Names Top 100 Teams Advancing Healthy Aging
The XPRIZE Healthspan competition announced its top 100 teams, spotlighting the core innovations of the 40 Milestone 1 award‑winning entrants. These teams are pursuing a spectrum of strategies—from mitochondrial‑targeted small molecules and metformin‑rapamycin combos to AI‑driven nutrition plans, senolytic drugs, and...
SportLinc Receives FDA Clearance: Lincotek Targets Orthopedic OEM Market
Lincotek’s SportLinc Syndesmosis Device has secured FDA 510(k) clearance (K252081), enabling commercial launch for ankle syndesmosis injuries. The single‑use system combines a high‑molecular‑weight polyethylene suture with low‑profile titanium buttons and arrives preloaded in a sterile inserter, streamlining operating‑room workflow. Lincotek...
A Study in Regulatory Conservatism versus Clinical Innovation
At today’s ODAC meeting, the FDA will review AstraZeneca’s oral selective estrogen receptor degrader camizestrant for hormone‑receptor‑positive, HER2‑negative breast cancer with ESR1 mutations. Late‑stage data showed a 56% reduction in risk of disease progression and consistent safety, along with improved...
Defect-Engineered Pt/Nb2O5 Boosts Radical-Driven Benzimidazole Production and Hydrogen Evolution Efficiency
Researchers have created a defect‑engineered Pt/Nb₂O₅ catalyst with abundant oxygen vacancies and platinum nanoparticles that dramatically improves photocatalytic benzimidazole synthesis and concurrent hydrogen evolution. The system delivers 4.0 mmol g⁻¹ h⁻¹ production of 2‑methylbenzimidazole and 10.2 mmol g⁻¹ h⁻¹ hydrogen under mild light, surpassing prior benchmarks....
DeNovix Launches Squid™ Full Range Pipette: A Single Device Covering 1 – 1000 µL
DeNovix unveiled the Squid™ Full Range Pipette, a single instrument that handles volumes from 1 µL to 1000 µL, effectively consolidating three to five conventional pipettes. The device uses Dynamic Volume Control™ with a patented tip selector, allowing users to switch between...
Nervous About Rehab? What to Actually Expect During Your First Visit
The article demystifies a first visit to inpatient addiction treatment, outlining the intake assessment, medically supervised detox, and the structured daily schedule that follows. It explains how personalized care plans are created from detailed health and substance‑use histories, and how...
Cold Plunges Under the Microscope: How Advanced Biomarker Testing and Wearable Technology Are Validating the Science of Cold Exposure
Cold plunges are shifting from anecdotal wellness trends to data‑driven interventions, thanks to wearable sensors and advanced biomarker testing. Wearables now capture heart‑rate variability, resting heart rate, and sleep patterns before, during, and after immersion, revealing how the autonomic nervous...
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
A wave of sizable financing rounds swept the biotech sector in late April 2026, with more than $1.3 billion pledged across 15 companies. Beeline Medicines led the pack with a $300 million Series A to advance lupus‑focused small‑molecule and protein therapeutics, while Sidewinder...
Single-Cell Sequencing Reveals Why some CAR-T Therapies Succeed While Others Fail
Researchers reviewed 44 single‑cell RNA sequencing studies covering about 500 patients to pinpoint cellular traits linked to CAR‑T therapy outcomes. The analysis identified exhaustion marker expression, low memory‑like cell fractions, and limited clonal diversity as hallmarks of relapse, while persistent,...
Health Care Money Splits Parties, Still Blocks Colorado Public Option
The health care industry gives roughly the same amount of money to Democrats and Republicans We couldn’t even get a true public option in Colorado
Cardiovascular Health 2026
Recent studies highlight pitavastatin’s pleiotropic benefits beyond LDL‑C reduction, including functional HDL elevation, enhanced cholesterol‑efflux capacity, and antioxidative actions in dyslipidemic patients. Pre‑clinical work shows the drug strengthens blood‑brain barrier integrity and mitigates lipopolysaccharide‑induced BBB dysfunction, suggesting neuroprotective potential. Real‑world...
Is Medical Detox the Same as It Used to Be? A Look at Addiction Care in 2026
By 2026 medical detox has shifted from a rigid, uncomfortable process to a data‑driven, patient‑centered experience. Advanced metabolic profiling lets physicians dose buprenorphine, benzodiazepines and other agents with pinpoint precision, while continuous biometric monitoring catches vital‑sign changes instantly. Intravenous nutrient...
FDA-Approved Marijuana Products and Those Subject to State-Issued Licenses Rescheduled; Marijuana Hearing Calendared; Dispensary Applications Accepted
Acting Attorney General Todd Blanche and the DEA issued a final rule that instantly reschedules FDA‑approved THC drug products and marijuana sold under state medical licenses from Schedule I to Schedule III of the Controlled Substances Act. The rule aligns federal regulation...
Map: Most States Are at Risk for Measles Outbreaks
Measles cases in the United States have surged from just 13 in 2020 to 2,228 in 2025, with nearly 1,800 reported in the first half of 2026. The spike follows a sharp decline in kindergarten‑age vaccination rates, which fell below...
Anti-Vaccine Activists Are Now the Majority in RFK, Jr.’s CDC Vaccine Panel
Health and Human Services Secretary Robert F. Kennedy Jr. has added four right‑wing, anti‑vaccine groups as liaison members to the CDC’s Advisory Committee on Immunization Practices (ACIP). The new charter expands ACIP’s remit to probe vaccine safety gaps and cumulative...
How America’s Medical System Encourages Psychiatric Overdiagnosis
Psychiatric diagnoses in the United States have surged across all age groups, with 59.3 million adults and nearly half of adolescents meeting criteria for at least one mental disorder in 2022. Proponents argue broader criteria improve detection, yet critics contend that...
IV Vitamin Therapy Could Change Your Life — by Killing You
A Mexican IV vitamin therapy clinic in Hermosillo saw eight of 11 patients die after receiving unsupervised vitamin drips, which authorities suspect were contaminated with bacteria. The treatment, marketed as a quick fix for dehydration, fatigue, and hangovers, has been...
What Drove Down America’s Fentanyl Deaths?
U.S. fentanyl overdose deaths fell sharply after mid‑2023, dropping nearly 50% by September 2025. Researchers link the decline to a supply shock, citing reduced fentanyl seizures, lower purity, and a surge in Reddit mentions of a "fentanyl drought." The shock appears...
Generally Good Indian Pharma Companies
An audit of top‑tier Indian generic manufacturers evaluated options for 20 therapeutic compounds, ranking firms by market capitalization, API vertical integration, ANDA volume, and GMP compliance. Cipla, Abbott, Sun Pharma, Zydus, Biocon and others were highlighted for specific products such...
Why Some Hospitals Won’t Be Able to Comply With Upcoming HIPAA Updates
The Department of Health and Human Services will finalize the first major HIPAA overhaul in more than a decade, scrapping the distinction between “required” and “addressable” rules and making every security provision mandatory. New mandates cover two‑factor authentication, data encryption,...
Can Your Surroundings Make or Break Your Recovery? Why Environment Matters in Addiction Treatment
Addiction recovery hinges on more than medication and willpower; the surrounding environment plays a decisive role. Removing patients from familiar triggers, immersing them in nature‑rich settings, and providing a warm, structured atmosphere lower stress hormones and enable deeper therapeutic work....
CCS Deploys Enterprise‑Wide Agentic AI, Targeting 30% Cost Savings
CCS announced it has become the first chronic‑care management organization to deploy an enterprise‑wide agentic AI platform, CeeCee™, projected to slash annual operating costs by more than 30% and autonomously handle a quarter of incoming patient calls within four months....
Midol Label Warns About Prostate Issues for Men
I’ve always wondered who wrote the label for Midol Complete (indicated for relief of menstrual symptoms). Because it says “ask a doctor before use if you have difficulty in urination due to enlargement of the prostate gland.” (Read that...
Balancing Care: Saving Others as Her Own Breath Fades
She was learning to keep others breathing while losing her own air [PODCAST] http://dlvr.it/TSHrbF Podcast #Pulmonology
Restoring Vision with Stem Cell–Derived Retinal Cells by Overcoming ILM Barrier
Researchers have shown that disrupting the internal limiting membrane (ILM) enables transplanted human pluripotent stem cell‑derived retinal ganglion cells (hRGCs) to survive, migrate, and mature in the retina of mice, rats and non‑human primates. In eyes with a genetically incomplete...
Biotech Liquidation Opportunities: ENDI, FNCH, LQDA Outlook
Please find Arquitos Capital's Q1 2026 letter below. I discuss opportunities in liquidating biotechs, $ENDI $FNCH and the range of potential outcomes for $LQDA. https://t.co/LJCczZ04W6
Covid Vaccine Rollout Keeps Getting Delayed, Like Trump's Plan
the schedule for when the covid vaccine time bomb is finally going to go off keeps getting pushed back like trump's healthcare plan lmao
New Copper Nanozyme Shows Powerful Tumor Suppression with High Precision
Researchers at the Chinese Academy of Sciences have created a coordinatively unsaturated copper single‑atom nanozyme (Cu‑N₂‑CDs) that exhibits markedly higher catalytic activity than traditional Cu‑N₄ nanozymes. The unsaturated Cu‑N₂ sites boost H₂O₂ adsorption by 3.49 times and generate hydroxyl radicals 3.62 times...
Australia’s Plasma Shortage Threatens Health and Costs
Could plasma be the new climate change? My column on how Australia's dwindling blood - and plasma - stocks are becoming an expensive problem. Perhaps the answer lies in the office if the right incentives are offered: https://t.co/m966D8rei1 (plus #Metallica...
Calcium Supplements Linked to Higher Cardiovascular Event Recurrence
Association Between Calcium Supplementation and Recurrence of Cardiovascular Events in Patients With Cardiovascular Disease: A Population‐Based Cohort Study 👉 “Caution should be exercised” https://t.co/ynmqMB4Zd0
American Heart Association Declares Brain Health a Lifelong, Multifactorial Process
The American Heart Association released a peer‑reviewed scientific statement, “Brain Health Across the Life Span: A Framework for Future Studies,” outlining how mental, physical, environmental and lifestyle factors influence brain health from early life through old age. The statement, published...
ONAVIDA Study Finds High‑Protein Oral Supplement Improves Recovery in Malnourished Cancer Patients
The ONAVIDA trial, published on 29 April 2026, demonstrated that a novel concentrated high‑protein, high‑calorie oral nutritional supplement (cHPHC‑ONS) significantly enhanced nutritional and morphofunctional recovery in 230 malnourished cancer patients over three months. The prospective, multicenter study combined the supplement...
Astorg to Acquire Thermo Fisher’s Microbiology Unit for $1.1 Billion
European private‑equity firm Astorg has signed a deal to purchase Thermo Fisher Scientific’s microbiology business for roughly $1.075 billion in cash and a $50 million seller note. The transaction, slated to close in the second half of the year, positions Astorg to...
Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Boosting Obesity Drug Race
Zealand Pharma reported that its dual GLP‑1/glucagon agonist survodutide produced an average 16.6% body‑weight reduction in a Phase 3 obesity trial. The data, presented from the SYNCHRONIZE‑1 study, also showed 85.1% of patients lost at least 5% of weight versus 38.8%...
Exercise Proven to Reduce Biological (Epigenetic) Age
What is the most established intervention linked to lower biological (epigenetic) age? Exercise A new systematic review @LancetLongevity of 44 studies, >145,000 participants https://t.co/agmAazwDxs
3Shape's AI Dental Imaging Software Gets FDA 510(k) Clearance
Denmark‑based 3Shape announced that the U.S. FDA granted 510(k) clearance for its Dx dental imaging suite, enabling American dental clinics to deploy AI‑assistive diagnostics for caries, plaque, wear and gingival recession. The approval opens a new revenue channel and marks...
The Knowledge, Attitude, and Practice Score on Oral Nutrition Supplementation Is Inversely Associated with Malnutrition Risk of Tumor Patients During...
A multicenter cross‑sectional study of 1,737 Chinese cancer patients undergoing radiotherapy found that 70.1% were at risk of malnutrition. Researchers measured patients' knowledge, attitude, and practice (KAP) toward oral nutrition supplements (ONS) and discovered that higher KAP scores were independently...
Association Between Planetary Health Diet Index and Lung Cancer Risk in 106,542 Participants: A Prospective Cohort Study
A prospective analysis of 106,542 participants from the PLCO trial found that higher adherence to the Planetary Health Diet Index (PHDI) was associated with a 29% lower risk of lung cancer over an average 8.8‑year follow‑up. Individuals in the highest...
Nutritional Properties of Extracellular Vesicle-Like Particles From Sophora Flavescens and Periplaneta Americana with Effects on Streptozotocin-Induced Diabetic Wound Healing in...
Researchers combined extracellular vesicle‑like particles (EVLPs) from the medicinal plant Sophora flavescens and the insect Periplaneta americana, creating a cross‑kingdom nano‑nutritional formulation (SF‑PA‑EVLPs). In streptozotocin‑induced diabetic rats, high‑dose SF‑PA‑EVLPs achieved roughly 90% wound closure within 14 days, outperforming the standard...
NeoGenomics Q1 2026 Revenue Jumps 11% as COO Warren Stone Charts Aggressive Sales Expansion
NeoGenomics reported first‑quarter 2026 revenue of $186.7 million, an 11% year‑over‑year increase that beat guidance and prompted a lift in full‑year outlook. President and COO Warren Stone used the call to unveil a sales‑force expansion and deeper community‑oncology coverage aimed at...